At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
Tezepelumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)
In Brief
A Phase 2 clinical trial evaluating Tezepelumab and Placebo for Asthma and 8 related conditions. Completed, enrolled 116 participants across 28 sites in 5 countries.
Detailed Summary
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
CountriesCanada, Denmark, Germany, United Kingdom, United States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionNov 2020
TodayJul 2026
First PostedSep 28, 2018
Enrollment StartNov 2, 2018
Primary CompletionNov 16, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.8 years ago
Interventions
Tezepelumabbiological
Tezepelumab subcutaneous injection
Placeboother
Placebo subcutaneous injection